Mutant p53-Driven Tumorigenesis

Chapter

Abstract

Most tumors inactivate the p53 tumor suppressor pathway via single nucleotide changes of the TP53 gene itself, which produces proteins with missense mutations. p53 mutant proteins clearly lose normal p53 activities. Some are partial loss of function mutations that retain some activities and probably cooperate with other changes in the p53 pathway to initiate tumor development. Many p53 mutants also exhibit gain-of-function and dominant negative properties. Several mouse models with p53 missense mutations have been generated and these now offer opportunities to study the effects of chemotherapeutic modalities.

Keywords

Lymphoma Codon Adenocarcinoma Sarcoma Oligomerization 

References

  1. Appella E, Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764–2772PubMedGoogle Scholar
  2. Barboza JA, Liu G, Ju Z et al (2006) p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 103:19842–19847PubMedGoogle Scholar
  3. Brachmann RK, Vidal M, Boeke JD (1996) Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 93:4091–4095PubMedGoogle Scholar
  4. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701–713PubMedGoogle Scholar
  5. Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19:1245–1256PubMedGoogle Scholar
  6. Cadwell C, Zambetti GP (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15–30PubMedGoogle Scholar
  7. Caulin C, Nguyen T, Lang GA et al (2007) An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117:1893–1901PubMedGoogle Scholar
  8. Chuikov S, Kurash JK, Wilson JR et al (2004) Regulation of p53 activity through lysine methylation. Nature 432:353–360PubMedGoogle Scholar
  9. de Vries A, Flores ER, Miranda B et al (2002) Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 99:2948–2953PubMedGoogle Scholar
  10. Dearth LR, Qian H, Wang T et al (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28:289–298PubMedGoogle Scholar
  11. Deppert W, Gohler T, Koga H et al (2000) Mutant p53: “gain of function” through perturbation of nuclear structure and function? J Cell Biochem Suppl Suppl 35:115–122PubMedGoogle Scholar
  12. Deyoung MP, Ellisen LW (2007) p63 and p73 in human cancer: defining the network. Oncogene 26:5169–5183PubMedGoogle Scholar
  13. Di Como CJ, Gaiddon C, Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19:1438–1449PubMedGoogle Scholar
  14. Donehower LA (2009) Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol 1:a001081PubMedGoogle Scholar
  15. Donehower LA, Lozano G (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831–841PubMedGoogle Scholar
  16. Donehower LA, Harvey M, Vogel H et al (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 14:16–22PubMedGoogle Scholar
  17. Donehower LA, Harvey M, Slagle BL et al (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221PubMedGoogle Scholar
  18. Eliyahu D, Goldfinger N, Pinhasi-Kimhi O et al (1988) Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3:313–321PubMedGoogle Scholar
  19. Epstein CB, Attiyeh EF, Hobson DA et al (1998) p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors. Oncogene 16:2115–2122PubMedGoogle Scholar
  20. Farmer G, Bargonetti J, Zhu H et al (1992) Wild-type p53 activates transcription in vitro. Nature 358:83–86PubMedGoogle Scholar
  21. Figueiredo BC, Sandrini R, Zambetti GP et al (2006) Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43:91–96PubMedGoogle Scholar
  22. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093PubMedGoogle Scholar
  23. Flores ER, Sengupta S, Miller JB et al (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7:363–373PubMedGoogle Scholar
  24. Gaiddon C, Lokshin M, Ahn J et al (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21:1874–1887PubMedGoogle Scholar
  25. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606PubMedGoogle Scholar
  26. Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81–137PubMedGoogle Scholar
  27. Harvey M, McArthur MJ, Montgomery CA Jr et al (1993) Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7:938–943PubMedGoogle Scholar
  28. Harvey M, Vogel H, Morris D et al (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305–311PubMedGoogle Scholar
  29. Haupt Y, Maya R, Kazaz A et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299PubMedGoogle Scholar
  30. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25–27PubMedGoogle Scholar
  31. Hwang SJ, Cheng LS, Lozano G et al (2003a) Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113:238–243PubMedGoogle Scholar
  32. Hwang SJ, Lozano G, Amos CI et al (2003b) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72:975–983PubMedGoogle Scholar
  33. Jacks T, Remington L, Williams BO et al (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1–7PubMedGoogle Scholar
  34. Jackson MW, Berberich SJ (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20:1001–1007PubMedGoogle Scholar
  35. Jeffrey PD, Gorina S, Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498–1502PubMedGoogle Scholar
  36. Jones SN, Roe AE, Donehower LA et al (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208PubMedGoogle Scholar
  37. Jones SN, Hancock AR, Vogel H et al (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95:15608–15612PubMedGoogle Scholar
  38. Kato S, Han SY, Liu W et al (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424–8429PubMedGoogle Scholar
  39. Kern SE, Kinzler KW, Baker SJ et al (1991) Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 6:131–136PubMedGoogle Scholar
  40. Kern SE, Pietenpol JA, Thiagalingam S et al (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830PubMedGoogle Scholar
  41. Koch JG, Gu X, Han Y et al (2007) Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 18:300–309PubMedGoogle Scholar
  42. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedGoogle Scholar
  43. Kraiss S, Quaiser A, Oren M et al (1988) Oligomerization of oncoprotein p53. J Virol 62:4737–4744PubMedGoogle Scholar
  44. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303PubMedGoogle Scholar
  45. Kuperwasser C, Hurlbut GD, Kittrell FS et al (2000) Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 157:2151–2159PubMedGoogle Scholar
  46. Lang GA, Iwakuma T, Suh YA et al (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861–872PubMedGoogle Scholar
  47. Laurie NA, Donovan SL, Shih CS et al (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61–66PubMedGoogle Scholar
  48. Lavigueur A, Maltby V, Mock D et al (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982–3991PubMedGoogle Scholar
  49. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749–758PubMedGoogle Scholar
  50. Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752PubMedGoogle Scholar
  51. Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26:2220–2225PubMedGoogle Scholar
  52. Liu G, McDonnell TJ, de Oca M, Luna R et al (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174–4179PubMedGoogle Scholar
  53. Liu G, Parant JM, Lang G et al (2004) Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36:63–68PubMedGoogle Scholar
  54. Liu DP, Song H, Xu Y (2010) A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29:949–956PubMedGoogle Scholar
  55. Lozano G (2007) The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 17:66–70PubMedGoogle Scholar
  56. Lozano G, Liu G (1998) Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol 8:337–344PubMedGoogle Scholar
  57. Luo JL, Yang Q, Tong WM et al (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20:320–328PubMedGoogle Scholar
  58. Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238PubMedGoogle Scholar
  59. Mardis ER (2011) A decade’s perspective on DNA sequencing technology. Nature 470:198–203PubMedGoogle Scholar
  60. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127:1323–1334PubMedGoogle Scholar
  61. Meek DW (1994) Post-translational modification of p53. Semin Cancer Biol 5:203–210PubMedGoogle Scholar
  62. Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11:685–696PubMedGoogle Scholar
  63. Milner J, Medcalf EA (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765–774PubMedGoogle Scholar
  64. Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245PubMedGoogle Scholar
  65. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206PubMedGoogle Scholar
  66. Morton JP, Timpson P, Karim SA et al (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107:246–251PubMedGoogle Scholar
  67. Muller PA, Caswell PT, Doyle B et al (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139:1327–1341PubMedGoogle Scholar
  68. Olive KP, Tuveson DA, Ruhe ZC et al (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847–860PubMedGoogle Scholar
  69. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629PubMedGoogle Scholar
  70. Pfeifer GP, Hainaut P (2011) Next-generation sequencing: emerging lessons on the origins of human cancer. Curr Opin Oncol 23:62–68PubMedGoogle Scholar
  71. Poyurovsky MV, Prives C (2006) Unleashing the power of p53: lessons from mice and men. Genes Dev 20:125–131PubMedGoogle Scholar
  72. Prives C, White E (2008) Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev 22:1259–1264PubMedGoogle Scholar
  73. Resnick MA, Inga A (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100:9934–9939PubMedGoogle Scholar
  74. Riley T, Sontag E, Chen P et al (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402–412PubMedGoogle Scholar
  75. Roemer K (1999) Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 380:879–887PubMedGoogle Scholar
  76. Rovinski B, Benchimol S (1988) Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2:445–452PubMedGoogle Scholar
  77. Rowan S, Ludwig RL, Haupt Y et al (1996) Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15:827–838PubMedGoogle Scholar
  78. Sakaguchi K, Herrera JE, Saito S et al (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831–2841PubMedGoogle Scholar
  79. Sharp DA, Kratowicz SA, Sank MJ et al (1999) Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 274:38189–38196PubMedGoogle Scholar
  80. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2:103–112PubMedGoogle Scholar
  81. Shvarts A, Steegenga WT, Riteco N et al (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15:5349–5357PubMedGoogle Scholar
  82. Shvarts A, Bazuine M, Dekker P et al (1997) Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics 43:34–42PubMedGoogle Scholar
  83. Song H, Hollstein M, Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573–580PubMedGoogle Scholar
  84. Stad R, Little NA, Xirodimas DP et al (2001) Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2:1029–1034PubMedGoogle Scholar
  85. Strano S, Fontemaggi G, Costanzo A et al (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277:18817–18826PubMedGoogle Scholar
  86. Terzian T, Suh YA, Iwakuma T et al (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22:1337–1344PubMedGoogle Scholar
  87. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923PubMedGoogle Scholar
  88. Tsuda H, Hirohashi S (1994) Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 57:498–503PubMedGoogle Scholar
  89. van Oijen MG, Slootweg PJ (2000) Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6:2138–2145PubMedGoogle Scholar
  90. Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21:313–320PubMedGoogle Scholar
  91. Varley JM, McGown G, Thorncroft M et al (1997a) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252PubMedGoogle Scholar
  92. Varley JM, Thorncroft M, McGown G et al (1997b) A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14:865–871PubMedGoogle Scholar
  93. Varley JM, McGown G, Thorncroft M et al (1999) Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65:995–1006PubMedGoogle Scholar
  94. Venkatachalam S, Shi YP, Jones SN et al (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657–4667PubMedGoogle Scholar
  95. Ventura A, Kirsch DG, McLaughlin ME et al (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665PubMedGoogle Scholar
  96. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310PubMedGoogle Scholar
  97. Wagner J, Portwine C, Rabin K et al (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707–1710PubMedGoogle Scholar
  98. Wang Y, Suh YA, Fuller MY et al (2011) Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121:893–904PubMedGoogle Scholar
  99. Wu CC, Shete S, Amos CI et al (2006) Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 66:8287–8292PubMedGoogle Scholar
  100. Xiong S, Pant V, Suh YA et al (2010) Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70:7148–7154PubMedGoogle Scholar
  101. Xue W, Zender L, Miething C et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of Colorado DenverAuroraUSA
  2. 2.Center for Regenerative Medicine and Stem Cell Biology, University of Colorado DenverAuroraUSA
  3. 3.Department of GeneticsUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations